Indiana biopharma outfit, Endocyte, has picked up exclusive worldwide license of PSMA-617 from ABX GmbH in a $12 million deal.
The company intends to move quickly into Phase 3 development of 177Lu-PSMA-617 – a radioligand therapeutic that targets the prostate-specific membrane antigen (PSMA), present in approximately 80% of patients with metastatic castration-resistant prostate cancer.
Mike Sherman, president and CEO of Endocyte, said: “We intend to seek regulatory approval to initiate a Phase 3 registration trial of 177Lu-PSMA-617 in early 2018. By focusing the company’s resources on the execution of this program, we project trial completion as early as 2020.”
PSMA-617 was developed at DKFZ (German Cancer Research Center) and University Hospital Heidelberg and exclusively licensed to ABX GmbH in Germany for early clinical development.